Windows en Linux
Houdt de toets ctrl ingedrukt en draai het muiswiel omhoog of omlaag
Of houdt de toets ctrl ingedrukt en druk tegelijk op de toets + of -
Of ga rechtsboven naar instellingen en gebruik de instelling zoom
Mac
Houdt de toets command ingedrukt en druk op de toets + of -
Of ga rechtsboven naar instellingen en gebruik de instelling zoom.
Trials / Protocollen
ABL001/asciminib
A phase III, multi-center, open-label, randomized study of oral asciminib versus Investigator selected TKI in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase| Ziektebeeld: | Chronisch myeloide leukemie (CML) |
| Behandellijn: | N.v.t. |
| Status: | Gearchiveerd |
| PI: | Dr. S.K. Klein |
| TC: | Sanne van der Kooi |
ALXN1210-TMA-313
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Ravulizumab in Adult and Adolescent Participants who have Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplant (HSCT)| Ziektebeeld: | Trombotische trombocytopenische purpura (of microangiopathieën) |
| Behandellijn: | N.v.t. |
| Status: | Open |
| PI: | Dr. C.L.E. Hazenberg |
| TC: | Sanne van der Kooi |
AMG 701
A Phase 1/2 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 701 Monotherapy, or in Combination with Pomalidomide, with and without Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma (ParadigMM-1B)| Ziektebeeld: | Multipel myeloom |
| Behandellijn: | >= 2de lijn |
| Status: | Gesloten voor inclusie |
| PI: | Dr. W.J. Plattel |
| TC: | M. de Vries |
AMG360
Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia With Safety Run-in (Golden Gate Study)| Ziektebeeld: | Acute lymfatische leukemie (ALL) en lymfoblastair lymfoom (LBL) |
| Behandellijn: | 1ste lijn |
| Status: | Open |
| PI: | Dr. T. van Meerten |
| TC: | Maryleen van Zanten |
Anakinra / AFFECT 2
Anakinra: Efficacy of interleukin-1 pathway inhibitor anakinra for the management of fever during neutropenia and mucositis in patients with multiple myeloma receiving an autologous hematopoietic stem cell transplantation after high-dose melphalan – A randomized controlled trial| Ziektebeeld: | Multipel myeloom |
| Behandellijn: | 1ste lijn |
| Status: | Gesloten voor inclusie |
| PI: | Dr. M. Bakker |
| TC: | M. de Vries |
BGB-3111-306
A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation| Ziektebeeld: | Mantelcellymfoom (MCL) |
| Behandellijn: | >= 2de lijn |
| Status: | Gepland |
| PI: | Dr. T. van Meerten |
| TC: | Margriet Dijkstra |
Biomea Covalent-101
COVALENT-101: A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral, covalent, menin inhibitor, in adult patients with acute leukemia (AL), diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), and chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL)| Ziektebeeld: | Diffuus grootcellig B-cel NHL, Chronisch lymfatische leukemie (CLL) small lymphocytic lymphoma (SLL), Multipel myeloom, AML (incl. APL) |
| Behandellijn: | >= 2de lijn |
| Status: | Open |
Cartitude 2 / 68284528MMY2003
A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma| Ziektebeeld: | Multipel myeloom |
| Behandellijn: | >= 2de lijn |
| Status: | Gesloten voor inclusie |
| PI: | Dr. W.W.H. Roeloffzen |
| TC: | M. de Vries |
Cartitude 4 / 68284528MMY3002
A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA, versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects with Relapsed and Lenalidomide-Refractory Multiple Myeloma| Ziektebeeld: | Multipel myeloom |
| Behandellijn: | >= 2de lijn |
| Status: | Gesloten voor inclusie |
| PI: | Dr. W.W.H. Roeloffzen |
| TC: | M. de Vries |
Cartitude 5 / 68284528MMY3004
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy| Ziektebeeld: | Multipel myeloom |
| Behandellijn: | 1ste lijn |
| Status: | Gesloten voor inclusie |
| PI: | Dr. W.W.H. Roeloffzen |
| TC: | M. de Vries |
Cartitude-6 (EMN28/68284528MMY3005)
A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and examethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in Participants with Newly Diagnosed Multiple Myeloma who are Transplant Eligible| Ziektebeeld: | Multipel myeloom |
| Behandellijn: | 1ste lijn |
| Status: | Open |
| PI: | Dr. W.W.H. Roeloffzen |
| TC: | Sanne van der Kooi |
CD8 imaging CAR T
A phase 2 immunoPET imaging study with ZED88082A/CED88004S in patients with Large B-cell lymphoma before and after CD19-directed CAR T-cell therapy| Ziektebeeld: | Diffuus grootcellig B-cel NHL |
| Behandellijn: | >= 2de lijn |
| Status: | Gesloten voor inclusie |
| PI: | Dr. T. van Meerten |
| TC: | Margriet Dijkstra |
CMBG453B12301
A randomized, double-blind, placebo-controlled phase III multi-center study of azacitidine with or without MBG453 for the treatment of patients with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)| Ziektebeeld: | Myelodysplastisch syndroom |
| Behandellijn: | 1ste lijn |
| Status: | Gesloten voor inclusie |
| PI: | Prof. Dr. G.A. Huls |
| TC: | Sanne van der Kooi |
DALY-2
A pivotal Phase II randomised, multi-centre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in participants with relapsed/refractory diffuse large B-cell lymphoma (R-R DLBCL), who are not eligible for high-dose chemotherapy and autologous stem cell transplantation| Ziektebeeld: | Diffuus grootcellig B-cel NHL |
| Behandellijn: | >= 2de lijn |
| Status: | Open |
| PI: | Dr. T. van Meerten |
| TC: | Margriet Dijkstra |
EFC17757/ROCKnrol-1
A randomized, double-blind, multicentre, Phase 3 study to evaluate efficacy and safety of belumosudil in combination with in combination with corticosteroids in participants at least 12 years of age with newly diagnosed chronic graft versus host disease (cGVHD).| Ziektebeeld: | Chronic graft versus host disease (cGVHD) |
| Behandellijn: | N.v.t. |
| Status: | Open |
| PI: | Dr. Goda Choi |
| TC: | Sanne v.d. Kooi/ Wilma Hartstra |
Enhance-3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab versus Placebo in Combination with Venetoclax and Azacitidine in Newly Diagnosed, Previously Untreated Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy| Ziektebeeld: | AML (incl. APL) |
| Behandellijn: | N.v.t. |
| Status: | Tijdelijk gesloten |
| PI: | Prof. Dr. G.A. Huls |
| TC: | Sanne van der Kooi |
Enhance/5F9009
A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination with Azacitidine versus Azacitidine Plus Placebo in Treatment-naïve Patients with Higher Risk Myelodysplastic Syndrome| Ziektebeeld: | Myelodysplastisch syndroom |
| Behandellijn: | 1ste lijn |
| Status: | Gesloten voor inclusie |
| PI: | Prof. Dr. G.A. Huls |
| TC: | Sanne van der Kooi |
EPCORE DLBCL-2
A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP Compared to R-CHOP in Subjects with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (EPCORE DLBCL-2)| Ziektebeeld: | Diffuus grootcellig B-cel NHL |
| Behandellijn: | 1ste lijn |
| Status: | Open |
| PI: | Dr. M. Nijland |
| TC: | Imke Kraai |
GCT3013-03
A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter’s Syndrome| Ziektebeeld: | Chronisch lymfatische leukemie (CLL) small lymphocytic lymphoma (SLL) |
| Behandellijn: | >= 2de lijn |
| Status: | Open |
| PI: | Dr. M. Bellido |
| TC: | Margriet Dijkstra |
Get-8
A phase 1/2 open-label safety and dose-finding study of BAY 2599023 (DTX201), an adeno-associated virus (AAV) hu37-mediated gene transfer of B-domain deleted human factor VIII, in adults with severe hemophilia A| Ziektebeeld: | Hemofilie A en B |
| Behandellijn: | N.v.t. |
| Status: | Gearchiveerd |
| PI: | Meijer |
| TC: | Karen Thedinga |
HaploMUD
Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients with Acute Leukemia with Identical GVHD Prophylaxis – A Randomized Prospective European Trial.| Ziektebeeld: | Allogene stamceltransplantatie |
| Behandellijn: | >= 2de lijn |
| Status: | Gesloten voor inclusie |
| PI: | Dr. C.W. Choi |
| TC: | Sanne van der Kooi |
| Leeftijd: | 18 - 71 |
Hope-B
Phase III, open-label, single-dose, multi-center multinational trial investigating a serotype 5 adeno-associated viral vector containing the Padua variant of a codon-optimized human factor IX gene (AAV5-hFIXco-Padua, AMT-061) administered to adult subjects with severe or moderately severe hemophilia B| Ziektebeeld: | Hemofilie A en B |
| Status: | Gesloten voor inclusie |
| PI: | Meijer |
| TC: | Karen Thedinga |
Hovon 119
Efficacy of alternating immunochemotherapy consisting of RCHOP + R-HAD versus R-CHOP alone, followed by maintenance therapy consisting of additional lenalidomide with rituximab versus rituximab alone for older patients with mantle cell lymphoma| Ziektebeeld: | Mantelcellymfoom (MCL) |
| Behandellijn: | 1ste lijn |
| Status: | Gesloten voor inclusie |
| PI: | Dr. T. van Meerten |
| TC: | Margriet Dijkstra |
Hovon 133
TRIANGLE autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized European mcl network trial| Ziektebeeld: | Mantelcellymfoom (MCL) |
| Behandellijn: | 1ste lijn |
| Status: | Gesloten voor inclusie |
| PI: | Dr. T. van Meerten |
| TC: | Margriet Dijkstra |
Hovon 136
Phase I-II study combining Brentuximab Vedotin with second line salvage chemotherapy (R-DHAP) in CD30 positive diffuse large B-cell lymphoma patients refractory to first line chemotherapy or in first relapse who are eligible for high dose treatment followed by autologous stem cell transplantation| Ziektebeeld: | Diffuus grootcellig B-cel NHL |
| Behandellijn: | >= 2de lijn |
| Status: | Gesloten voor inclusie |
| PI: | Dr. M. Nijland |
| TC: | K. Thedinga |
Hovon 138
A randomized Phase III study to compare arsenic trioxide (ATO) combined to ATRA and idarubicin versus standard ATRA and anthracycLines-based chemotherapy (AIDA regimen) for patients with newly diagnosed, high-risk acute prOmyelocytic leukemia.| Ziektebeeld: | AML (incl. APL) |
| Behandellijn: | 1ste lijn |
| Status: | Gesloten voor inclusie |
| PI: | Prof. Dr. G.A. Huls |
| TC: | Sanne van der Kooi |
| Leeftijd: | 18 - 65 |
Hovon 140
CLL13-TRIAL OF THE GCLLSG IN COOPERATION WITH HOVON, NORDIC CLL STUDY GROUP, SAKK, CANCER TRIALS IRELAND AND THE ISRAELI CLL STUDY GROUP| Ziektebeeld: | Chronisch lymfatische leukemie (CLL) small lymphocytic lymphoma (SLL) |
| Behandellijn: | 1ste lijn |
| Status: | Gesloten voor inclusie |
| PI: | Dr. M. Bellido |
| TC: | K. Thedinga |
Hovon 141
A prospective, multicenter, phase-II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥ 30 ml/min who have relapsed or refractory chronic lymphocytic leukemia (RR-CLL) with or without TP53 aberrations| Ziektebeeld: | Chronisch lymfatische leukemie (CLL) small lymphocytic lymphoma (SLL) |
| Behandellijn: | 1ste lijn |
| Status: | Gesloten voor inclusie |
| PI: | Dr. M. Bellido |
| TC: | K. Thedinga |
Hovon 150 (IDH2 cohort gesloten)
A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy.| Ziektebeeld: | AML (incl. APL) |
| Behandellijn: | 1ste lijn |
| Status: | Open |
| PI: | Dr. Ammatuna |
| TC: | Sanne van der Kooi |
Hovon 151
A phase II study evaluating the feasibility and clinical efficacy of atezolizumab consolidation treatment in high risk diffuse large B-cell lymphoma| Ziektebeeld: | Diffuus grootcellig B-cel NHL |
| Behandellijn: | 1ste lijn |
| Status: | Gesloten voor inclusie |
| PI: | Dr. M. Nijland |
| TC: | K. Thedinga |
| Leeftijd: | 18 - 75 |
Hovon 152
A phase II study evaluating the effect of DA-EPOCH-R induction followed by nivolumab consolidation in patients with newly diagnosed high grade B cell lymphoma (HGBL) with MYC and BCL2 and/or BCL6 rearrangements| Ziektebeeld: | Non-Hodgkin lymfomen (NHL) |
| Behandellijn: | 1ste lijn |
| Status: | Gesloten voor inclusie |
| PI: | Dr. M. Nijland |
| TC: | K. Thedinga |
Hovon 155
A randomized phase II multicenter study to assess the tolerability and efficacy of the addition of midostaurin to 10-day decitabine in unfit (i.e. HCT-CI ≥ 3) adult AML and high risk myelodysplasia (MDS) (IPSS-R > 4.5) patients| Ziektebeeld: | AML (incl. APL) |
| Behandellijn: | 1ste lijn |
| Status: | Gesloten voor inclusie |
| PI: | Dr. Ammatuna |
| TC: | Sanne van der Kooi |
Hovon 156
A phase 3, multicenter, open-label, randomized, study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by one-year maintenance in patients with newly diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy| Ziektebeeld: | AML (incl. APL) |
| Behandellijn: | 1ste lijn |
| Status: | Gesloten voor inclusie |
| PI: | Dr. Ammatuna |
| TC: | Sanne van der Kooi |
Hovon 164
Tislelizumab plus Gemcitabine and Cisplatin for Relapsed or Refractory Hodgkin Lymphoma followed by Tislelizumab Consolidation in Patients in Metabolic Complete Remission (TIGERR-HL). An open label phase II trial.| Ziektebeeld: | Hodgkin lymfoom |
| Behandellijn: | >= 2de lijn |
| Status: | Open |
| PI: | Dr. W.J. Plattel |
| TC: | Margriet Dijkstra |
Hovon 171
A single arm phase II trial to assess cobicistat boosted venetoclax in combination with azacitidine (sc) in adult patients with newly diagnosed acute myeloid leukaemia (AML) who are not considered candidates for intensive treatment regimens| Ziektebeeld: | AML (incl. APL) |
| Behandellijn: | 1ste lijn |
| Status: | Open |
| PI: | Prof. Dr. G.A. Huls |
| TC: | Sanne van der Kooi |
ISKIA / HO503
Phase III study of Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone (Isa-KRd) versus Carfilzomib-Lenalidomide-Dexamethasone (KRd) in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation (IsKia TRIAL)| Ziektebeeld: | Multipel myeloom |
| Behandellijn: | 1ste lijn |
| Status: | Gesloten voor inclusie |
| PI: | Dr. W.W.H. Roeloffzen |
| TC: | K. Thedinga |
LBL-Registry
A Prospective, Multicenter, Observational Study of Real-Life Current Standards of Care in Patients with lymphoblastic lymphoma including the evaluation with FDG-PET-CT scintigraphy| Ziektebeeld: | Acute lymfatische leukemie (ALL) en lymfoblastair lymfoom (LBL) |
| Behandellijn: | N.v.t. |
| Status: | Open |
| PI: | dr M (Mar) Bellido |
M16-191
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)| Ziektebeeld: | Primaire myelofibrose |
| Behandellijn: | N.v.t. |
| Status: | Gesloten voor inclusie |
| PI: | Dr. Ammatuna |
| TC: | Sanne van der Kooi |
M20-638
Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2 ) compared to R2 in Subjects with Relapsed or Refractory Follicular Lymphoma (EPCORE™ FL-1)| Ziektebeeld: | Folliculair NHL |
| Behandellijn: | >= 2de lijn |
| Status: | Open |
| PI: | Dr. M. Nijland |
| TC: | M. Dijkstra |
MajesTEC-3 / 64007957MMY3001
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC (Tec-Dara) versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants with Relapsed or Refractory Multiple Myeloma| Ziektebeeld: | Multipel myeloom |
| Behandellijn: | 1ste lijn |
| Status: | Gesloten voor inclusie |
| PI: | Dr. W.J. Plattel |
| TC: | M. de Vries |
MajesTEC-4
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation| Ziektebeeld: | Multipel myeloom |
| Behandellijn: | 1ste lijn |
| Status: | Open |
| PI: | Dr. W.W.H. Roeloffzen |
| TC: | Corine Habraken |
MajesTEC-9 / 64007957MMY3006
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide| Ziektebeeld: | Multipel myeloom |
| Behandellijn: | >= 2de lijn |
| Status: | Open |
| PI: | Dr. W.W.H. Roeloffzen |
| TC: | Corine Habraken |
MGD006-01
A Phase 1/2, First-in-Human, Dose Escalation Study of MGD006, a CD123 x CD3 Dual Affinity Re-Targeting (DART) Bi-Specific Antibody-Based Molecule, in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Intermediate-2/High Risk Myelodysplastic Syndrome| Ziektebeeld: | AML (incl. APL) |
| Behandellijn: | >= 2de lijn |
| Status: | Gearchiveerd |
| PI: | Prof. Dr. G.A. Huls |
| TC: | Sanne van der Kooi |
| Leeftijd: | 18 - 65 |
MP0533-CP101
A phase 1/2a, first-in-human, open-label, multicenter, dose escalation study of MP0533 in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)| Ziektebeeld: | Myelodysplastisch syndroom, AML (incl. APL) |
| Behandellijn: | >= 2de lijn |
| Status: | Open |
PD-L1 PET
Programmed death ligand 1 (PD-L1)-PET imaging in patients with (Diffuse) Large B-cell Lymphoma who are treated with CD19-directed CAR T-cell therapy: a pilot study| Ziektebeeld: | Diffuus grootcellig B-cel NHL |
| Behandellijn: | >= 2de lijn |
| Status: | Open |
| PI: | Dr. T. van Meerten |
| TC: | Margriet Dijkstra |
Prothena AFFIRM-AL / NEOD001-301
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis| Ziektebeeld: | Amyloïdose |
| Behandellijn: | >= 2de lijn |
| Status: | Open |
| PI: | Dr. W.W.H. Roeloffzen |
| TC: | M. de Vries |
| Leeftijd: | 18 - 75 |
RADAR
A randomized phase III trial with a PET response adapted design comparing ABVD +/- ISRT with A2VD +/- ISRT in patients with previously untreated stage IA/IIA Hodgkin lymphoma.| Ziektebeeld: | Hodgkin lymfoom |
| Behandellijn: | >= 2de lijn |
| Status: | Open |
| PI: | Dr. T.W. Plattel |
| TC: | Maryleen van Zanten |
| Leeftijd: | 16 - 69 |
SAR443579 – TCD17197
An open-label, first-in-human, dose-escalation study of SAR443579 administered as single agent by intravenous infusion in patients with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL) or high riskmyelodysplasia (HR-MDS)| Ziektebeeld: | Myelodysplastisch syndroom, Acute lymfatische leukemie (ALL) en lymfoblastair lymfoom (LBL), AML (incl. APL) |
| Behandellijn: | >= 2de lijn |
| Status: | Tijdelijk gesloten |
| PI: | Prof. Dr. G.A. Huls |
| TC: | Sanne van der Kooi |
Shine
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma| Ziektebeeld: | Mantelcellymfoom (MCL) |
| Behandellijn: | 1ste lijn |
| Status: | Gearchiveerd |
| PI: | Dr. M. Nijland |
| TC: | Margriet Dijkstra |
Trispecific Antibody (79635322MMY1001)
Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants with Relapsed or Refractory Multiple Myeloma or Previously Treated AL Amyloidosis| Ziektebeeld: | Multipel myeloom |
| Behandellijn: | >= 2de lijn |
| Status: | Open |
| PI: | Dr. W.W.H. Roeloffzen |
| TC: | Corine Habraken |
Vaccinstop
Vaccination response to pneumococcal antigen as novel predictor for successful tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia: the vaccinSTOP study| Ziektebeeld: | Chronisch myeloide leukemie (CML) |
| Behandellijn: | N.v.t. |
| Status: | Gesloten voor inclusie |
| PI: | Dr. S.K. Klein |
| TC: | Sanne van der Kooi |
XPORT-MF-034-Karyopharm
A Phase 1/3 study to evaluate the efficacy and safety of Selinexor, a selective inhibitor of nuclear export, in combination with Ruxolitinib in treatment-naïve patients with myelofibrosis.| Ziektebeeld: | Primaire myelofibrose |
| Behandellijn: | N.v.t. |
| Status: | Open |
| PI: | Dr. Emanuele Ammatuna |
| TC: | Wilma Hartstra |
ZUMA-7
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)| Ziektebeeld: | Diffuus grootcellig B-cel NHL |
| Behandellijn: | >= 2de lijn |
| Status: | Gesloten voor inclusie |
| PI: | Dr. T. van Meerten |
| TC: | Margriet Dijkstra |
ZUMA23
An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma (ZUMA-23)| Ziektebeeld: | High-Grade B-Cell Lymphoma (HGBCL) |
| Behandellijn: | 1ste lijn |
| Status: | Open |
| PI: | Dr. T. van Meerten |
| TC: | Maryleen van Zanten |